Search
Sonesitatug Vedotin
go.drugbank.com/drugs/DB18619InvestigationalCMG901 is an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payload.
Synonyms: an anti-Claudin 18.2 monoclonal antibody conjugated with MMAE payloadZotarolimus
go.drugbank.com/drugs/DB18761InvestigationalZotarolimus is an immunosuppressant under investigation for use in drug-eluting stents.
APT3111
go.drugbank.com/drugs/DB06390ExperimentalAPT3111 is an investigational drug used to treat PNH (paroxysmal nocturnal haemoglobinurea).
Dental Mesenchymal Pulp Stem Cells
go.drugbank.com/drugs/DB15737InvestigationalThey are harvested through surgical extraction of wisdom teeth from adults; this procedure is favoured as it is non-invasive, easily accessible, and allows for an alternate use of teeth that are usually … Dental pulp is a soft, connective tissue present in the dental crown of both third molar and first premolar teeth.
SSR-126517E
go.drugbank.com/drugs/DB05362ExperimentalSSR-126517E is a second generation synthetic pentasaccharide that binds antithrombin with such high affinity that it assumes a plasma half-life of 80 hours.
CEP-1347
go.drugbank.com/drugs/DB05403InvestigationalCEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons
(4R)-limonene
go.drugbank.com/drugs/DB08921InvestigationalAs the main odor constituent of citrus (plant family Rutaceae), D-limonene is used in food manufacturing and some medicines, e.g. as a flavoring to mask the bitter taste of alkaloids, and as a fragrant
Uridine diphosphate glucose
go.drugbank.com/drugs/DB01861ExperimentalAlso serves as a precursor of sucrose lipopolysaccharides, and glycosphingolipids. … Serves as a precursor of glycogen, can be metabolized into UDPgalactose and UDPglucuronic acid which can then be incorporated into polysaccharides as galactose and glucuronic acid.
AZD0947
go.drugbank.com/drugs/DB04848ExperimentalAs of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline. … AZD0947 is a K+ channel opener, which was under investigation by AstraZeneca for the treatment of overactive bladder.